Emerging agents for onychomycosis

B. M. Piraccini; M. Iorizzo; G. Rech; A. Tosti

Emerging agents for onychomycosis

B. M. Piraccini, M. Iorizzo, G. Rech, A. Tosti

Research output: Contribution to journal › Review article › peer-review

Abstract

Onychomycosis is the most common nail disease and describes the invasion of the nail by fungi. In most cases, treatment of onychomycosis requires systemic antifungals, with duration of administration ranging from 2 to several months. Cure rates range from 60% to 80%, and relapses are not rare (up to 20% of patients). New antifungals providing higher cure rates and less relapses are, therefore, auspicable. A review of onychomycoses and their treatment is made and the new antifungal drugs that are currently on study or already available are presented.

Original language	English (US)
Pages (from-to)	155-159
Number of pages	5
Journal	Giornale Italiano di Dermatologia e Venereologia
Volume	141
Issue number	2
State	Published - Apr 2006
Externally published	Yes

Keywords

Antimicotics
Nails
Posaconazole
Ravuconazole
Voriconazole

ASJC Scopus subject areas

Dermatology

Access to Document

Fingerprint Dive into the research topics of 'Emerging agents for onychomycosis'. Together they form a unique fingerprint.

Cite this

@article{644a858e5fc249ceb7d31446cafff40d,

title = "Emerging agents for onychomycosis",

abstract = "Onychomycosis is the most common nail disease and describes the invasion of the nail by fungi. In most cases, treatment of onychomycosis requires systemic antifungals, with duration of administration ranging from 2 to several months. Cure rates range from 60% to 80%, and relapses are not rare (up to 20% of patients). New antifungals providing higher cure rates and less relapses are, therefore, auspicable. A review of onychomycoses and their treatment is made and the new antifungal drugs that are currently on study or already available are presented.",

keywords = "Antimicotics, Nails, Posaconazole, Ravuconazole, Voriconazole",

author = "Piraccini, {B. M.} and M. Iorizzo and G. Rech and A. Tosti",

year = "2006",

month = apr,

language = "English (US)",

volume = "141",

pages = "155--159",

journal = "Giornale Italiano di Dermatologia e Venereologia",

issn = "0392-0488",

publisher = "Edizioni Minerva Medica S.p.A.",

number = "2",

}

TY - JOUR

T1 - Emerging agents for onychomycosis

AU - Piraccini, B. M.

AU - Iorizzo, M.

AU - Rech, G.

AU - Tosti, A.

PY - 2006/4

Y1 - 2006/4

N2 - Onychomycosis is the most common nail disease and describes the invasion of the nail by fungi. In most cases, treatment of onychomycosis requires systemic antifungals, with duration of administration ranging from 2 to several months. Cure rates range from 60% to 80%, and relapses are not rare (up to 20% of patients). New antifungals providing higher cure rates and less relapses are, therefore, auspicable. A review of onychomycoses and their treatment is made and the new antifungal drugs that are currently on study or already available are presented.

AB - Onychomycosis is the most common nail disease and describes the invasion of the nail by fungi. In most cases, treatment of onychomycosis requires systemic antifungals, with duration of administration ranging from 2 to several months. Cure rates range from 60% to 80%, and relapses are not rare (up to 20% of patients). New antifungals providing higher cure rates and less relapses are, therefore, auspicable. A review of onychomycoses and their treatment is made and the new antifungal drugs that are currently on study or already available are presented.

KW - Antimicotics

KW - Nails

KW - Posaconazole

KW - Ravuconazole

KW - Voriconazole

UR - http://www.scopus.com/inward/record.url?scp=33646834300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646834300&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:33646834300

VL - 141

SP - 155

EP - 159

JO - Giornale Italiano di Dermatologia e Venereologia

JF - Giornale Italiano di Dermatologia e Venereologia

SN - 0392-0488

IS - 2

ER -